Most supplements marketed for visceral fat reduction have not been shown to meaningfully shrink the deep abdominal fat they claim to target. The best-designed human trials, including a 2025 randomized controlled trial of berberine, one of the most popular ingredients in this category, found no significant change in visceral fat area compared to placebo. A handful of ingredients show small, preliminary signals in short studies, but nothing close to the dramatic claims on supplement labels. The gap between what these products promise and what the clinical evidence actually supports is wide enough to matter for your wallet and your health.
Why Visceral Fat Gets Its Own Category of Supplements
Visceral fat is the fat stored deep in the abdomen, packed around organs like the liver, pancreas, and intestines. It behaves differently from the fat you can pinch under your skin. Data from the Framingham Heart Study found that visceral fat was far more strongly linked to metabolic problems than subcutaneous fat. Among women, each standard-deviation increase in visceral fat raised the odds of metabolic syndrome roughly four- to fivefold, compared to about threefold for subcutaneous fat. The pattern held in men as well.1PubMed. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study Visceral fat is also a risk factor for insulin resistance, type 2 diabetes, and dyslipidemia in ways that subcutaneous fat is not, partly because visceral fat cells have distinct structural and metabolic characteristics.2PubMed Central. Metabolic alterations following visceral fat removal and expansion: Beyond anatomic location
This distinction is what supplement companies exploit. Because visceral fat carries outsized health risks, there is a natural market for products that claim to target it specifically. The trouble is that selectively reducing fat from one internal depot is not something any supplement has convincingly demonstrated in humans. Your body does not burn fat from specific locations on demand, and deep abdominal fat is no exception.
Berberine and the AMPK Promise
Berberine, a compound found in plants like goldenseal and barberry, has become one of the most talked-about supplements for metabolic health. It activates an enzyme called AMPK, which plays a role in how cells manage energy. In animal studies and cell-culture experiments, berberine shows an impressive range of effects: increased fat breakdown, reduced formation of new fat cells, and shifts in gut bacteria that favor metabolic health.3PubMed Central. Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence At typical preclinical doses, berberine also influences cholesterol absorption and glucose metabolism in animals.4PubMed. The effect of Berberine on weight loss in order to prevent obesity: A systematic review
The problem is what happens when you move from mice to people with a placebo control. A 2025 randomized clinical trial published in JAMA Network Open enrolled adults with obesity and metabolic-associated liver disease who did not have diabetes. After months of supplementation, there was no significant difference in visceral fat area between the berberine and placebo groups. The placebo group actually saw a slightly larger average reduction (about 2%) than the berberine group (about 0.6%). Berberine also did not significantly improve liver fat content, blood sugar markers, insulin resistance, or body composition. Where berberine did outperform placebo was in modestly lowering LDL cholesterol and an inflammatory marker called hs-CRP.5JAMA Network Open. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial
That result is a useful reality check. Berberine may have legitimate effects on cholesterol and inflammation, but the specific claim that it reduces visceral fat did not hold up in a well-designed human trial. The animal data looked promising; the human data did not follow.
Green Tea Catechins
Green tea extract, especially its catechin compounds, is another staple in visceral fat supplements. A double-blind, placebo-controlled trial in adults with high proportions of visceral fat found that those drinking a catechin-enriched green tea beverage had a statistically significant reduction in visceral fat area after 12 weeks, while the control group did not.6Journal of Functional Foods. Effects of catechin-enriched green tea beverage on visceral fat loss in adults with a high proportion of visceral fat: A double-blind, placebo-controlled, randomized trial Animal data supports this direction too: mice fed a high-fat, high-sugar diet showed reduced visceral fat gains when supplemented with tea polyphenols.7The Journal of Nutrition. Tea Polyphenol Extracts Reduce Body Fat, Inflammation, and Obesity-Associated Angiogenesis and Affect Gut Microbiota in C57BL/6J Mice Fed an High-Fat/High-Sucrose Diet
The catechin story looks stronger than berberine at first glance, but there are caveats that supplement labels do not mention. The effects in humans are modest, often amounting to a few square centimeters of visceral fat area over several months. The health effects of polyphenols also depend heavily on how much is absorbed and how the body processes them, and results across studies are inconsistent, probably because of differences in study design, population demographics, and the chemical form of the polyphenol used.8PubMed Central. Anti-Obesity Effects of Polyphenol Intake: Current Status and Future Possibilities A supplement pill containing concentrated green tea extract is also a different product from a cup of brewed tea, and as covered later in this article, high-dose catechin extracts carry liver safety concerns that brewed tea does not.
Probiotics and Visceral Fat
Several probiotic strains have been tested specifically for their effects on visceral fat. A randomized, double-blind trial found that 12 weeks of supplementation with Lactobacillus gasseri BNR17 at a higher dose led to a significant decrease in visceral adipose tissue compared to placebo, with the difference amounting to about 22 square centimeters.9PubMed. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial A separate trial using a related strain, Lactobacillus gasseri SBT2055, delivered through fermented milk found that the active group had a roughly 4.6% drop in visceral fat area over the study period, while the control group showed no significant change.10European Journal of Clinical Nutrition. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial
These are among the more encouraging results in the supplement space, and they come from controlled trials rather than just rodent models. But they share a limitation common to almost every positive supplement trial: the studies are small, short, and sponsored by companies with commercial interest in the strains tested. A 4-5% reduction over a few months is real but modest, and nobody knows whether the effect persists once supplementation stops, or whether it extends to populations beyond obese Japanese adults (where much of this probiotic research has been conducted). The fact that specific strains matter also means a generic “probiotic blend” from the supplement aisle is unlikely to replicate these results.
Conjugated Linoleic Acid
Conjugated linoleic acid, or CLA, was one of the first supplements aggressively marketed for fat loss and remains widely available. The evidence for visceral fat specifically is a mess. One trial in obese men with signs of metabolic syndrome found that four weeks of CLA supplementation led to a significant decrease in a measure of abdominal fat diameter compared to placebo.11PubMed. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial But another trial in middle-aged men doing resistance training found the opposite: the CLA group showed no reduction in visceral fat, while the placebo group actually lost more visceral fat during the same period.12PubMed Central. Conjugated linoleic Acid supplementation does not reduce visceral adipose tissue in middle-aged men engaged in a resistance-training program
Beyond the inconsistent fat data, CLA raises safety questions that get too little attention. A meta-analysis noted that CLA can slightly increase markers of inflammation, including C-reactive protein and white blood cell counts. It has also been linked to increased insulin resistance, particularly with certain CLA isomers and in shorter-duration studies.13The American Journal of Clinical Nutrition. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans Worsening insulin resistance in a person trying to reduce visceral fat, itself strongly associated with insulin resistance, is the kind of trade-off that deserves more than a footnote on a bottle.
Capsaicinoids and Other Thermogenic Ingredients
Capsaicin, the compound that makes chili peppers hot, and its milder relatives called capsinoids activate receptors involved in heat production. In people who have metabolically active brown adipose tissue, a single oral dose of capsinoids can increase energy expenditure.14PubMed. Capsinoids and related food ingredients activating brown fat thermogenesis and reducing body fat in humans The mechanism mimics cold exposure, stimulating brown fat to burn calories as heat, and longer-term use may help recruit more brown fat over time.15Best Practice & Research Clinical Endocrinology & Metabolism. Activation and recruitment of brown adipose tissue by cold exposure and food ingredients in humans
That sounds compelling, but the energy expenditure bump from capsaicinoids is small, and it only occurs in people who already have active brown fat, a trait that varies enormously between individuals and tends to decline with age. There is no strong human evidence that taking a capsaicin supplement leads to meaningful visceral fat loss specifically. The thermogenic effect exists; its practical impact on deep abdominal fat over weeks or months has not been convincingly demonstrated in clinical trials.
L-Carnitine
Carnitine is heavily marketed as a fat-burning aid because it helps shuttle fatty acids into mitochondria for energy production. In aged rats, L-carnitine supplementation restored muscle cell carnitine levels, improved oxidative capacity, and reduced abdominal fat mass without any change in food intake.16The Journals of Gerontology: Series A. L-Carnitine Supplementation and Physical Exercise Restore Age-Associated Decline in Some Mitochondrial Functions in the Rat That animal result sounds promising, but reviews of the broader evidence find little support for carnitine as a weight-loss tool in humans.17PubMed. Dietary fat intake, supplements, and weight loss Most healthy people already have adequate carnitine levels, so supplementing does not meaningfully increase the rate at which their cells burn fat. The body simply excretes what it does not need.
Why Lab Results Rarely Survive the Trip to Your Gut
A pattern runs through all of these ingredients: strong effects in cell cultures and rodent models, followed by disappointing results in human trials. One of the biggest reasons is bioavailability. Many of the plant compounds in visceral fat supplements, including curcumin and the catechins in green tea, are poorly absorbed in the human digestive tract. They break down quickly, get metabolized before reaching meaningful concentrations in tissues, or simply pass through without being absorbed.
Research into workarounds shows that combining curcumin with piperine (from black pepper) can boost curcumin’s bioavailability up to 20-fold, and combining EGCG with caffeine modestly increased 24-hour energy expenditure by about 4% in humans.18PubMed Central. Synergistic Effects of Bioactive Compounds on Human Adiposity Mechanisms of Fat Loss and Fat Accumulation But most commercial supplements do not use these formulations, and even when they do, “better absorbed” does not automatically mean “effective at reducing visceral fat.” Boosting the absorption of a compound that has not proven its visceral-fat claim in the first place just means more of an unproven ingredient reaches your bloodstream.
Inflammation Markers vs. Actual Fat Loss
One area where some supplements do show consistent effects is in reducing inflammatory markers. A systematic review and network meta-analysis of randomized controlled trials in overweight and obese adults found that green tea extract and curcumin both significantly reduced the inflammatory signaling molecule IL-6. Curcumin, probiotics combined with omega-3, synbiotics, and zinc all lowered C-reactive protein, a broad marker of inflammation. Synbiotics also raised levels of adiponectin, a hormone associated with healthier fat tissue function.19PubMed Central. Effects of Nutritional Supplements on Inflammatory Biomarkers in Overweight and Obese Adults: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Lowering inflammation is genuinely valuable, because chronic low-grade inflammation is part of what makes visceral fat dangerous. But reducing an inflammatory blood marker and reducing the volume of visceral fat itself are not the same thing. Some supplement companies blur this distinction, presenting improvements in CRP or IL-6 as evidence of visceral fat loss when the two do not necessarily track together. You could theoretically reduce inflammation while your visceral fat stays the same, or even grows. The inflammation findings are real and potentially useful, but they do not validate the “visceral fat supplement” framing.
Safety Problems That Don’t Make the Label
Supplements marketed as fat burners carry risks that most buyers are not aware of. A case report described a young, otherwise healthy woman who developed acute liver failure requiring an emergency liver transplant after taking a dietary supplement containing usnic acid, green tea extract, and guggul tree extract.20PubMed Central. Acute liver failure caused by ‘fat burners’ and dietary supplements: a case report and literature review A separate case series documented liver injuries in four patients from different commercially available fat burners, including products containing green tea extract, Garcinia cambogia, green coffee beans, and spirulina. One of those patients also required a liver transplant, and another suffered severe hemorrhaging after a liver biopsy.21PubMed. Fat burner-induced acute liver injury: Case series of four patients
Green tea extract is a particularly instructive example because it is also the ingredient with some of the more positive visceral fat data. The main catechin in green tea extract, EGCG, has been shown to cause dose-dependent liver toxicity. High doses can destroy mitochondrial membranes and generate reactive oxygen species. The toxicity risk is also higher in fasted individuals, which is exactly the state many dieters are in when taking these supplements.22PubMed Central. Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review The irony is hard to miss: the people most motivated to take a concentrated green tea extract capsule on an empty stomach are the ones at highest risk for its most dangerous side effect.
How Supplements Compare to Prescription Drugs
It helps to have a benchmark. GLP-1 receptor agonists, the class of drugs that includes liraglutide and semaglutide, have been studied extensively for their effects on visceral fat. A systematic review and meta-analysis found that GLP-1 receptor agonists produced a large, statistically significant reduction in visceral adipose tissue across multiple populations, including people with and without type 2 diabetes.23PLOS ONE. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis The effect sizes from prescription drugs dwarf what any supplement has shown. This is not to suggest everyone should be on a GLP-1 drug, but it illustrates how far supplements fall short of the bar for clinically meaningful visceral fat reduction.
The comparison also highlights a measurement problem. Many supplement studies use waist circumference or bioelectrical impedance to estimate visceral fat. These are indirect proxies at best. The most reliable methods are CT and MRI scans, which directly image the fat depot.24PubMed. Measuring visceral and hepatic fat in clinical practice and clinical research Pharmaceutical trials routinely use imaging. Supplement trials often do not, which means even their positive results may be measuring something other than what they claim. A drop in waist circumference could reflect loss of subcutaneous fat, water, or simply variation in how the tape was held.
Menopause, Hormones, and Why Supplements Get Extra Attention
One group especially targeted by visceral fat supplement marketing is women going through or past menopause. The reason is physiological: perimenopause brings a significant drop in estrogen, which triggers a redistribution of fat from under the skin to the abdominal cavity. On average, visceral fat climbs from about 5-8% of total body fat before menopause to 15-20% afterward.25PubMed Central. Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review Estrogen deficiency is a central driver of this shift, reducing subcutaneous fat storage capacity and favoring visceral accumulation.26Clinical and Experimental Obstetrics & Gynecology. The Accumulation of Visceral Fat in Postmenopausal Women: the Combined Impact of Prenatal Genetics, Epigenetics, and Fat Depot Heterogeneity—A Descriptive Review
This is a real biological problem, and it makes postmenopausal women understandably receptive to products claiming to target visceral fat. But almost none of the supplement trials have been designed to study this population specifically, and the hormonal mechanism driving the fat shift is not something a plant extract is equipped to counteract. The supplements being sold to menopausal women for visceral fat are the same ones being sold to everyone else, and the evidence behind them is no stronger in this context. If anything, the age-related decline in brown adipose tissue activity makes thermogenic ingredients even less likely to be effective in older women than in the younger populations where they were originally tested.
What the Regulatory Environment Allows
In the United States, dietary supplements do not need to prove that they work before being sold. The FDA regulates supplements under different rules than drugs: manufacturers do not need to demonstrate efficacy through clinical trials, and the agency only steps in after a product is already on the market and causing harm. This is why products with essentially no evidence for visceral fat reduction can legally carry structure-function claims like “supports healthy body composition” or “promotes abdominal wellness.” Even after the FDA banned ephedra-containing supplements due to cardiovascular risks, a review of online retailers found that more than 10% of weight loss products assessed were in possible violation of that ban, with some still listing ephedrine or ephedra species on their labels.27PubMed Central. Online Marketing of Ephedra Weight Loss Supplements: Labeling and Marketing Compliance with the U.S. Food and Drug Administration Ban on Ephedra
The practical consequence is that “visceral fat supplement” is primarily a marketing category, not a medical one. The label tells you what the manufacturer wants to sell you. It does not tell you whether the product has ever been tested against the specific claim it is making, let alone whether it worked. The burden of proof falls on you, and the evidence, when you go looking for it, rarely supports the purchase.